"Lung Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the LUNG.
| Descriptor ID |
D008175
|
| MeSH Number(s) |
C04.588.894.797.520 C08.381.540 C08.785.520
|
| Concept/Terms |
Lung Neoplasms- Lung Neoplasms
- Pulmonary Neoplasms
- Neoplasms, Lung
- Lung Neoplasm
- Neoplasm, Lung
- Neoplasms, Pulmonary
- Neoplasm, Pulmonary
- Pulmonary Neoplasm
Lung Cancer- Lung Cancer
- Cancer, Lung
- Cancers, Lung
- Lung Cancers
- Pulmonary Cancer
- Cancer, Pulmonary
- Cancers, Pulmonary
- Pulmonary Cancers
- Cancer of the Lung
- Cancer of Lung
|
Below are MeSH descriptors whose meaning is more general than "Lung Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Lung Neoplasms".
This graph shows the total number of publications written about "Lung Neoplasms" by people in this website by year, and whether "Lung Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 11 | 5 | 16 |
| 1996 | 10 | 4 | 14 |
| 1997 | 9 | 0 | 9 |
| 1998 | 13 | 1 | 14 |
| 1999 | 8 | 4 | 12 |
| 2000 | 12 | 1 | 13 |
| 2001 | 12 | 5 | 17 |
| 2002 | 22 | 9 | 31 |
| 2003 | 32 | 13 | 45 |
| 2004 | 30 | 8 | 38 |
| 2005 | 35 | 10 | 45 |
| 2006 | 32 | 12 | 44 |
| 2007 | 41 | 10 | 51 |
| 2008 | 43 | 9 | 52 |
| 2009 | 36 | 4 | 40 |
| 2010 | 45 | 4 | 49 |
| 2011 | 54 | 11 | 65 |
| 2012 | 51 | 4 | 55 |
| 2013 | 58 | 5 | 63 |
| 2014 | 52 | 6 | 58 |
| 2015 | 74 | 9 | 83 |
| 2016 | 71 | 11 | 82 |
| 2017 | 65 | 3 | 68 |
| 2018 | 74 | 6 | 80 |
| 2019 | 76 | 7 | 83 |
| 2020 | 76 | 6 | 82 |
| 2021 | 89 | 3 | 92 |
| 2022 | 67 | 0 | 67 |
| 2023 | 70 | 0 | 70 |
| 2024 | 61 | 6 | 67 |
| 2025 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lung Neoplasms" by people in Profiles.
-
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. J Immunother Cancer. 2025 Feb 04; 13(2).
-
Preoperative Chest CT Myosteatosis Indicates Worse Postoperative Survival in Stage 0-IIB Non-Small Cell Lung Cancer. Radiology. 2025 Feb; 314(2):e240282.
-
Targeting CNS Metastases in Non-Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers: A Review. JAMA Oncol. 2025 Jan 01; 11(1):60-69.
-
NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2025. J Natl Compr Canc Netw. 2025 01; 23(1).
-
Clinical Utility of a Circulating Tumor Cell-Based Cerebrospinal Fluid Assay in the Diagnosis and Molecular Analysis of Leptomeningeal Disease in Patients With Advanced Non-Small Cell Lung Cancer. JCO Precis Oncol. 2024 Dec; 8:e2400373.
-
Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review. Lung Cancer. 2025 Jan; 199:108051.
-
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study. Neuro Oncol. 2024 Dec 05; 26(12):2316-2327.
-
Proposed Ninth Edition TNM Staging System for Lung Cancer: Guide for Radiologists. Radiographics. 2024 Dec; 44(12):e240057.
-
Breathing down resistance: Tackling hypoxia to overcome immunotherapy barriers in lung cancer. J Exp Med. 2025 Jan 06; 222(1).
-
Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): Alliance. Cancer. 2025 Jan 01; 131(1):e35663.